MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/4/2026

1. NKE
2. USO
3. SPY
4. ACN
5. NVDA
6. TRU
7. TLT
8. LAES
9. FICO
10. WBD

Go back to MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
(NASDAQ: MBX) Delayed: 58.51 +1.96 (3.47%)
Previous Close $56.55    52 Week High $ 
Open $59.28    52 Week Low $ 
Day High $61.12    P/E N/A 
Day Low $56.90    EPS $ 
Volume 637,324